The American Journal of Medicine
Volume 116, Issue 7 , Pages 474-477 , 1 April 2004

Health care lobbying in the United States

  • Steven H Landers, MD

      Affiliations

    • Department of Family Medicine, University Hospitals and Case Western Reserve University (SHL), Cleveland, Ohio, USA
    • ,
  • Ashwini R Sehgal, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Dr. Sehgal at the Division of Nephrology, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, Ohio 44109, USA
    • Center for Reducing Health Disparities, Center for Health Care Research and Policy, Division of Nephrology, Departments of Medicine, Biomedical Ethics, and Epidemiology and Biostatistics, MetroHealth Medical Center and Case Western Reserve University (ARS), Cleveland, Ohio, USA

Received 21 May 2003 ,Revised 20 October 2003 ,Accepted 20 October 2003.

References 

  1. Igleheart JK. Medicare's declining payments to physicians. N Engl J Med. 2002;346:1924–1930
  2. Gross CP, Anderson GF, Powe NR. The relationship between funding by the National Institutes of Health and the burden of disease. N Engl J Med. 1999;340:1881–1887
  3. Kulynych J, Korn D. The new federal medical-privacy rule. N Engl J Med. 2002;347:1133–1134
  4. Landers SH, Sehgal AR. How do physicians lobby their members of Congress?. Arch Intern Med. 2000;160:3248–3251
  5. United States Congress. Lobbying Disclosure Act of 1995. Public Law Number 104-65
  6. Baumgartner FR, Leech BL. Interest niches and policy bandwagons (patterns of interest group involvement in national politics). J Politics. 2001;63:1191–1213
  7. Center for Responsive Politics. Available at: http://www.opensecrets.org. Accessed January 3, 2002
  8. Brody H. A matter of influence (changing times call for changing policies on the presence of drug company reps in residency programs). Health Affairs. 2002;21:232–234
  9. Iglehart JK. Medicare and prescription drugs. N Engl J Med. 2001;344:1010–1015
  10. Chren MM, Landefeld CS. Physicians' behavior and their interaction with drug companies. J Am Med Assoc. 1994;271:684–689
  11. Wazana A. Physicians and the pharmaceutical industry (is a gift ever just a gift?). J Am Med Assoc. 2000;283:373–380
  12. Moore S, Wolfe SM, Lindes D, Douglas CE. Epidemiology of failed tobacco control legislation. J Am Med Assoc. 1994;272:1171–1175
  13. Sharfstein JM, Sharfstein SS. Campaign contributions from the American Medical Political Action Committee to members of Congress. For or against the public health?. N Engl J Med. 1994;330:32–37
  14. Bindman AB, Grumbach K, Bernheim S, et al.  Medicaid managed care's impact on safety-net clinics in California. Health Aff. 2000;19:194–202

PII: S0002-9343(03)00803-9

doi: 10.1016/j.amjmed.2003.10.037

The American Journal of Medicine
Volume 116, Issue 7 , Pages 474-477 , 1 April 2004

Article Tools

* Image Usage & Resolution